All ESMO Abstracts 2020

About
Consulting
Capabilities
Report Store
Insights
Login
Contact
Cart
0

Home
ESMO Conference 2020
All

Filters:
Targets/Technology

Immune Checkpoint Inhibitors

Classes showing abundant growth (PARP inhibitors, CDK4/6 inhibitors)

Others

Cell therapies (CAR-T/TCR/TCR2)

Promising new classes (viz.AKT inhibitors; BiTE)

multiTKI

Bispecific Antibodies
Indications

Others

Breast Cancer( HER2-ve; HER2+ve, TNBC)

Melanoma

Lung Cancer (NSCLC; SCLC)

Renal Cell Carcinoma (RCC)

Urothelial Carcinoma

Head and Neck Cancer

Colorectal Cancer

Glioblstoma; High Grade Glioma

Merkel cell carcinoma

Diffused Large B-Cell Lymphoma (DLBCL)

Prostate Cancer (HSPC, CRPC)

Ovarian Cancer

+ SHOW MORE

-- End of the Page --

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.